Compare GDRX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | NVCR |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2015 |
| Metric | GDRX | NVCR |
|---|---|---|
| Price | $2.93 | $10.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $3.95 | ★ $26.14 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 12-01-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 21.79 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $796,853,000.00 | $655,353,000.00 |
| Revenue This Year | $0.20 | $12.95 |
| Revenue Next Year | $4.73 | $9.33 |
| P/E Ratio | $100.50 | ★ N/A |
| Revenue Growth | 0.57 | ★ 8.28 |
| 52 Week Low | $1.77 | $9.82 |
| 52 Week High | $3.89 | $21.45 |
| Indicator | GDRX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 31.40 | 27.46 |
| Support Level | $2.83 | $10.14 |
| Resistance Level | $3.12 | $18.43 |
| Average True Range (ATR) | 0.19 | 0.69 |
| MACD | -0.07 | -0.16 |
| Stochastic Oscillator | 0.57 | 3.04 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.